Abbvie Inc (NYSE: ABBV) on Tuesday, plunged -2.82% from the previous trading day, before settling in for the closing price of $190.86. Within the past 52 weeks, ABBV’s price has moved between $163.52 and $218.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 11.11% annually for the last half of the decade. The company achieved an average annual earnings per share of 20.82%. With a float of $1.76 billion, this company’s outstanding shares have now reached $1.77 billion.
In an organization with 55000 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 77.46%, operating margin of 28.31%, and the pretax margin is 6.31%.
Abbvie Inc (ABBV) Insider and Institutional Ownership
Observing investor behavior towards Drug Manufacturers – General industry stocks is more important than anything else. The insider ownership of Abbvie Inc is 0.09%, while institutional ownership is 74.11%. The most recent insider transaction that took place on Mar 31 ’25, was worth 12,359,504. In this transaction EVP, CHIEF COMMERCIAL OFFICER of this company sold 58,832 shares at a rate of $210.08, taking the stock ownership to the 53,234 shares. Before that another transaction happened on Mar 31 ’25, when Company’s Officer proposed sale 58,832 for $210.09, making the entire transaction worth $12,359,897.
Abbvie Inc (ABBV) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 20.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.22% during the next five years compared to -14.67% drop over the previous five years of trading.
Abbvie Inc (NYSE: ABBV) Trading Performance Indicators
Abbvie Inc (ABBV) is currently performing well based on its current performance indicators. A quick ratio of 0.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.71. Likewise, its price to free cash flow for the trailing twelve months is 21.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.35, a number that is poised to hit 3.22 in the next quarter and is forecasted to reach 13.99 in one year’s time.
Technical Analysis of Abbvie Inc (ABBV)
Let’s dig in a bit further. During the last 5-days, its volume was 4.72 million. That was inferior than the volume of 6.97 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 48.23%. Additionally, its Average True Range was 4.30.
During the past 100 days, Abbvie Inc’s (ABBV) raw stochastic average was set at 38.86%, which indicates a significant increase from 25.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 15.76% in the past 14 days, which was lower than the 30.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $184.85, while its 200-day Moving Average is $188.78. However, in the short run, Abbvie Inc’s stock first resistance to watch stands at $189.05. Second resistance stands at $192.62. The third major resistance level sits at $194.63. If the price goes on to break the first support level at $183.47, it is likely to go to the next support level at $181.46. The third support level lies at $177.89 if the price breaches the second support level.
Abbvie Inc (NYSE: ABBV) Key Stats
Market capitalization of the company is 327.63 billion based on 1,766,403K outstanding shares. Right now, sales total 56,334 M and income totals 4,278 M. The company made 13,343 M in profit during its latest quarter, and 1,286 M in sales during its previous quarter.
